The World Health Organization says insufficient surveillance over the past 40 years has led to the re-emergence of yaws disease in rural marginalized populations in Africa, Asia and South America. The illness leads to the destruction of skin, cartilage and bone, often leaving victims disfigured and susceptible to other infections.
The condition, which is caused by the penetration of bacterial spirochetes into cuts and abrasions in the skin, was virtually eradicated by the WHO's global control program that ran from 1952 to 1964, that saw 300 million people worldwide receive preventative treatment. Today, however, the incidence of the disease is increasing, with more than 500,000 individuals around the world thought to be infected.
The WHO's director of neglected tropical diseases, Lorenzo Savioli, said that "the persistence of yaws in the 21st century is unacceptable," explaining that it can be successfully treated with a long-acting dose of penicillin that costs as little as $0.32 per person. Dr Sovioli added that current research suggests that the disease could eventually be eradicated by a global treatment effort because humans are the only natural reservoir for the infection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze